Life-Threatening Pulmonary Hemorrhage Responds to Recombinant Factor VIIa: A Case Series in South Florida Hospitals

Intravenous recombinant activated Factor VIIa (rFVIIa) is approved as a hemostatic agent for only a few bleeding disorders. Since the first reported case of off-label use for rFVIIa in 1999, off-label use far exceeds the use for approved conditions. The endobronchial administration of rFVIIa to cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Raiko, Almeida, Patricia, Alvarez, Michael, Ferrer, Gustavo, Hernandez, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Pulmonology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925373/
https://www.ncbi.nlm.nih.gov/pubmed/31890404
http://dx.doi.org/10.7759/cureus.6202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925373/
https://www.ncbi.nlm.nih.gov/pubmed/31890404
http://dx.doi.org/10.7759/cureus.6202

Ejemplares similares